1. We are a small market in the grand scheme of things. It will come but it's not make or break if approval is delayed.
2. Australian Surgeons can (and do) get access to CardioCel through the Special Access Scheme. So it's not like they can't get a hold of it.
From what I understand, TGA approval is not high on the agenda for Admedus. Quite rightly so they focusing on the US, Europe and Asia where the real gains in growing this company can and will be made. It's not always about the "bloody" Government shafting hardworking Australian technology companies.
AHZ Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
